Sensus Links Skin Cancer Tech to Cloud, Unlocking New Growth Strategy

BOCA RATON, FL – February 26, 2026 – Sensus Healthcare, a medical device company specializing in non-invasive skin cancer treatments, has introduced Sensus Link, a new cloud-based software solution designed to bring advanced operational capabilities to its extensive installed base of superficial radiotherapy (SRT) systems. The move is poised to enhance treatment delivery in clinics across the country while marking a pivotal strategic shift for the Nasdaq-listed company toward a cloud-centric, recurring revenue business model.

Sensus Link combines a new point-of-care software platform with cloud connectivity, intended to upgrade the company’s widely adopted SRT-100™ systems. This initiative aims to provide clinicians using the base model with sophisticated tools that were previously exclusive to more advanced, high-end platforms.

Upgrading the Standard of Care

For years, Sensus Healthcare’s SRT-100 system has been a workhorse in dermatology and oncology clinics, offering a non-surgical alternative for treating non-melanoma skin cancers and keloids. While effective, the base system's data management and workflow capabilities were distinct from the company's premium offerings, such as the SRT-100 Vision, which integrates high-frequency ultrasound imaging and a more robust workstation for treatment planning and documentation.

Sensus Link effectively closes this gap. The software upgrade provides users with enhanced workflow management, streamlined treatment documentation, and access to critical operating intelligence. By delivering these features via a cloud-connected platform, Sensus is democratizing access to top-tier technology. Clinics with existing SRT-100 machines can now leverage functionalities that improve clinical efficiency, ensure operational consistency, and simplify the documentation process required for billing and compliance.

“Sensus Link is the first of several exciting innovations that will allow us to offer a streamlined integration of the latest technological advancements to both existing and new SRT-100 customers,” noted Carlton Chow, Chief Technology Officer of Sensus Healthcare, in the official announcement.

This enhancement is expected to have a tangible impact on patient care. With more sophisticated data tracking and workflow tools, clinicians can manage treatment courses more effectively, ensuring greater precision and consistency from one session to the next. For a busy practice, this efficiency can translate to more focused patient interactions and optimized clinic schedules.

A Confluence of Technology and Policy

The timing of the Sensus Link launch is no coincidence. It arrives on the heels of significant regulatory tailwinds that are reshaping the financial landscape for superficial radiotherapy. According to company leadership, the initiative is designed to build upon recently enacted reimbursement codes that make SRT treatments more economically attractive for healthcare providers.

Earlier this month, Sensus highlighted the publication of new dedicated Current Procedural Terminology (CPT) codes for SRT, which provide greater clarity and financial predictability for clinics offering the service. This development addresses a critical barrier to adoption, as practices are more likely to invest in new technology when they have confidence in the reimbursement structure. The new codes are expected to bolster the financial case for SRT as a primary treatment option for non-melanoma skin cancer.

“Building upon recently enacted reimbursement codes that significantly improve physician economics for superficial radiotherapy, our priority is to broaden access to the full Sensus operating experience across our installed base,” said Joe Sardano, Chairman and Chief Executive Officer of Sensus Healthcare. Sensus Link is positioned as the technological key that allows clinics to unlock the full value of this improved reimbursement environment by making their SRT operations more efficient and easier to manage.

A Strategic Pivot to the Cloud

Beyond the immediate clinical benefits, Sensus Link represents a foundational piece of a much larger corporate strategy. The company has explicitly framed the launch as the first step in its broader 'Sensus Cloud™' initiative, signaling a deliberate pivot from a business model reliant on one-time hardware sales to one that embraces recurring software and service revenue.

This strategic shift is particularly timely. Recent financial reports indicate the company has faced market headwinds, making the development of new, stable revenue streams a top priority. Sensus Link “creates a scalable recurring revenue opportunity tied to treatment workflows and required oversight services,” Sardano explained. This software-as-a-service (SaaS) model is common in the tech industry but is now increasingly being adopted by medical device manufacturers to foster deeper customer relationships and create more predictable financial performance.

By connecting its devices to the cloud, Sensus also gains capabilities for enhanced remote serviceability and data analytics, which can inform future product development and provide greater value to its customers. This transition to an integrated hardware-software ecosystem is critical for long-term growth and competitiveness in the evolving med-tech landscape.

Fortifying a Competitive Position

As a pioneer in the field, Sensus Healthcare has long held a leading position in the market for non-invasive skin cancer treatments, facing competition from companies like Xstrahl. The launch of Sensus Link is a strategic move to fortify that position. By providing a significant upgrade path for its large installed base, the company can increase customer loyalty and prevent attrition to competitors.

Furthermore, the enhanced platform makes the SRT-100 a more compelling offering for new customers. The combination of a proven hardware system with a modern, cloud-connected software interface aligns with the expectations of today’s tech-savvy medical practices. This is further supported by the company’s flexible acquisition models, including direct purchase and “Fair Deal Agreements,” as well as its recently launched financial services arm designed to lower adoption barriers.

“As we move into 2026, we believe Sensus Link will strengthen our commercial offering across both direct purchase and Fair Deal Agreement customers,” Sardano added, emphasizing the software’s role in making the technology more accessible. “Importantly, it enables practices to adopt an enhanced operating platform while maintaining flexibility in how they acquire and use our technology.”

Sensus Healthcare plans to begin a phased commercial rollout of Sensus Link during 2026, offering the solution to both new and eligible existing customers. This careful deployment will allow the company to manage customer onboarding and ensure a smooth transition for practices adopting the new system. This integration of hardware, software, and cloud connectivity represents a significant step in the ongoing evolution of oncological treatment delivery.